martes, 24 de abril de 2012

WHO Pharmaceuticals Newsletter No. 2, 2012 • 3

ya esta disponible un nuevo numero
con el siguiente contenido


Regulatory Matters
Aliskiren containing medicines ....... 4
Atomoxetine .............................4
Boceprevir.. .......................... .4
Bortezomib............................. 5
Citalopram hydrobromide .............6
Domperidone ............................7
Fluoroquinolone......................... 7
Pneumovax® 23 (pneumococcal vaccine polyvalent) ...8
Statins ....................................8
Strontium ranelate .....................8
Vandetanib...............................9


Safety of Medicines
Aprotinin ...............................10
Benzyl alcohol-containing parentral products ...10
Blue dyes ...............................11
Doripenem .............................11
Fingolimod .............................12
Orlistat-containing medicines........12
Proton Pump Inhibitors (PPIs) ........13
Statins and HIV or Hepatitis C Protease inhibitors......14

Signal
Donepezil – SSRI and SNRI – interaction and Serotonin syndrome ................................................15
esponse from Marketing Authorization Holders (MAH) regarding a signal of Donepezil and Serotonin Syndrome .......19
Ranolazine and Hallucination .......21
Response from MAH regarding a signal of Ranolazine and Hallucination...23

Feature
Empowering patients in pharmacovigilance: current developments in WHO ......26

disponible en

http://www.who.int/entity/medicines/publications/newsletter/Newsletter_2_2012.pdf